In the first section of Figure 4, we present the levels of CSF sCD163, serum sCD163, and ratio sCD163 for 13 treated and eight untreated patients with CIS/RRMS at the time of diagnosis and after a minimum of 1 year follow‐up time. This evidence concerns the gene CSF2 and in situ carcinoma.